Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

288.00DKK
8:29pm IST
Change (% chg)

kr.0.50 (+0.17%)
Prev Close
kr.287.50
Open
kr.284.00
Day's High
kr.288.20
Day's Low
kr.283.65
Volume
2,202,734
Avg. Vol
3,107,145
52-wk High
kr.354.80
52-wk Low
kr.260.20

Select another date:

Fri, Jun 8 2018

Novo Nordisk shares fall after report of layoffs

COPENHAGEN Shares in Novo Nordisk opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets.

Novo Nordisk considers laying-off up to 3,000 staff - Danish paper Borsen

COPENHAGEN, June 7 Novo Nordisk is considering laying-off up to 3,000 staff and dropping its long-term financial targets due to challenging market conditions in the United States, Danish daily Borsen reported Thursday citing unnamed sources.

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON/COPENHAGEN Novo Nordisk said data from a large final-stage study of a pill it hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance.

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

BRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion

* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION

BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme

* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME

BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018

May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:

UPDATE 1-Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

* Positive feedback on new Ozempic drug (Adds detail, guidance in Danish crowns)

Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.

BRIEF-Novo Nordisk Beats Q1 Expectations; Lifts 2018 Guidance A Tad

* OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018

Select another date: